Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Her-2 polypeptide and composition for tumor and preparation method and application

A her-2 and composition technology, applied in the field of protein peptides, can solve the problems of weak immunogenicity, poor therapeutic effect, different tumor vaccine epitopes, etc., and achieve the effects of low side effects and significant curative effect.

Inactive Publication Date: 2017-07-07
ADLAI NORTYE BIOPHARMA CO LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The problems of the prior art solved by the present invention are: the existing tumor vaccines have the disadvantages of different epitopes, weak immunogenicity and poor therapeutic effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Her-2 polypeptide and composition for tumor and preparation method and application
  • Her-2 polypeptide and composition for tumor and preparation method and application
  • Her-2 polypeptide and composition for tumor and preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0092] The present invention provides the synthetic method of Her-2 short peptide for this reason, and its steps are as follows:

[0093] Step 1, in the presence of an activator system, the Fmoc-Glu (OtBu)-resin is obtained by coupling the resin solid phase carrier and Fmoc-Glu (OtBu)-OH;

[0094] Step 2, by solid-phase synthesis, sequentially coupling amino acids with N-terminal Fmoc protection and side chain protection according to the peptide sequence of the main chain peptide of the Her-2 / neu proto-oncogene family sequence;

[0095] Step 3, cracking, purifying, and freeze-drying to obtain the Her-2 / neu proto-oncogene family sequence peptide and its analogues.

[0096] Wherein, the resin solid carrier described in step 1 adopts 2-CTC resin, the activator system is selected from DIEA, TMP or NMM, and the Fmoc-Glu(OtBu)-resin is Fmoc-Glu(OtBu)-resin with a substitution degree of 0.30~0.70mmol / g. Glu(OtBu)-CTC resin can be synthesized by yourself or purchased directly.

[00...

Embodiment 1

[0127] SEQ ID No. 1:

[0128] Synthesis of H-Ser-Arg-Met-Ala-Arg-Asp-Pro-Gln-Arg-Phe-Val-Val-Ile-Gln-Asn-Glu-OH

[0129] (1) Weigh 0.1 mmol of Fmoc-Glu(OtBu)-CTC resin with a degree of substitution of 0.61 mmol / g, add it to a solid-phase reaction column, wash it once with DMF, and swell the Fmoc-Glu(OtBu)-CTC resin with DMF After 30 minutes, use a mixed solution of DMF:pyridine with a volume ratio of 4:1 to remove Fmoc protection, then wash with DMF for 6 times, weigh 0.5mmol of Fmoc-Asn(Trt)-OH, and 0.5mmol of HOBt, and add a volume ratio of A 1:1 mixed solution of DCM and DMF was activated by adding 80 μl DIC (0.5 mmol) in an ice-water bath, then added to the above-mentioned reaction column equipped with resin, and reacted at room temperature for 2 hours, and the ninhydrin method was used to detect and judge the reaction end point. If the resin is colorless and transparent, it means that the reaction is complete; if the resin develops color, it means that the reaction is in...

Embodiment 2

[0134] SEQ ID No.2:

[0135] Synthesis of H-Cys-Ala-His-Tyr-Lys-Asp-Pro-Pro-Phe-Cys-Val-Ala-Arg-Cys-Pro-Ser-OH

[0136] (1) Weigh 0.1 mmol of Fmoc-Ser(tBu)-CTC resin with a degree of substitution of 0.57 mmol / g, add it to a solid-phase reaction column, wash it once with DMF, and swell the Fmoc-Ser(tBu)-CTC resin with DMF After 30 minutes, use a mixed solution of DMF:pyridine with a volume ratio of 4:1 to remove Fmoc protection, then wash with DMF for 6 times, weigh 0.5mmol of Fmoc-Pro-OH, and add 0.5mmol of HOBt with a volume ratio of 1:1. The mixed solution of DCM and DMF was activated by adding 80μl DIC (0.5mmol) in an ice-water bath, and then added to the above-mentioned reaction column equipped with resin. If it is transparent, it means that the reaction is complete; if the resin is colored, it means that the reaction is incomplete and needs to be reacted for another 1 hour. This judgment standard is applicable to the ninhydrin method in the subsequent amino acid coupling...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of protein polypeptide, in particular to Her-2 polypeptide for tumor, a composition containing the same and a preparation method and application thereof. The sequence of the Her-2 polypeptide is selected from SEQ ID No.1, SEQ ID No.2, SEQ ID No.3 and SEQ ID No.4. The Her-2 polypeptide and the composition containing the same present good treatment effect and lower toxic and side effect on tumor, especially breast cancer, lymph cancer and prostate cancer or lung cancer and present good medicinal property.

Description

technical field [0001] The present invention relates to the field of protein polypeptides, in particular to a class of Her-2 polypeptides for tumors, compositions containing Her-2 polypeptides and their preparation methods and applications, and further applied to the preparation or treatment of prostate cancer, lymphoma, and lung cancer Especially breast cancer and other related diseases or related drugs. Background technique [0002] The Her-2 / neu gene was first discovered by Slamon and Alex in 1985. In 1987, Slamon et al. first pointed out that the overexpression of the Her-2 / neu gene was related to the recurrence and survival rate of breast cancer. Her-2 / neu was identified as a New tumor markers (Slamon DJ, Clark GM, Wong SG, et al. Science, 1987, 235(4785): 177-82). [0003] Her-2 / neu is a proto-oncogene, which is mainly expressed during embryonic development, and a small amount of expression can be detected in normal tissues after adulthood. Many human tumors, such as...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/47C07K1/06C07K1/04A61K38/17A61K39/00A61P35/00
CPCA61K38/17C07K1/04C07K1/06C07K14/47Y02P20/55A61K38/00A61K39/00A61K2039/6031A61K2039/6043A61K2039/6056
Inventor 张晓何南海厉保秋路杨杨东晖沈柯周俊
Owner ADLAI NORTYE BIOPHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com